Encouraging anti-tumor activity for patients with metastatic head & neck squamous cell carcinoma who are HPV-negative and treated with bifunctional EGFR/TGF-beta inhibitor BCA101 w/pembrolizumab.
BC A 101 is a targeted therapy um for EGFR expressing cancers or tumors. Um and it's a bispecificity GF beta uh trapping molecule. And this trial was a phase one study. Um This cohort is specifically for head and neck cancer patients combining BC A 101 an infusion weekly with the PD one inhibitor hem uh for again, advanced head and neck cancer patients in the first line. This included HPV, positive and negative patients with an immune um PDL one score, CPS, one or greater uh who had not had prior treatment. And overall the results show that the therapy in combination was well tolerated. There was expected skin toxicity. But importantly, for this class of TGF beta molecules, uh limited and low grade and manageable uh bleeding issues or risk. And excitingly, the overall response rate for the total cohort uh was 48%. And that was among 31 invaluable patients. But maybe more exciting was the response rate among 20 HPV negative patients, which was 65%. We're waiting for survival and progression free. Um uh metrics. Uh but many of the responses were durable. So we're very excited about these preliminary findings. Uh Hopefully this uh moves into a larger randomized uh potentially confirmatory trial in the future.
